Development of an in vitro metabolic dysfunction-associated steatohepatitis model to investigate altered drug metabolizing enzymes, transport proteins, and hepatobiliary disposition
These findings demonstrate that lipid-cytokine treatments induce MASH-like changes in SCHH, including clinically relevant reductions in DME and transporter concentrations and function. This model may serve as a valuable tool for predicting altered hepatobiliary drug disposition in MASH.
Authors
- Henry Ho (ORCID: https://orcid.org/0000-0003-1138-9149)
- Elaine M. Leslie (ORCID: https://orcid.org/0000-0003-1825-348X)
- William A. Murphy (ORCID: https://orcid.org/0000-0002-7476-9248)
- Sarina Kyburz
- Thomas Kralj
- Jacqueline B. Tiley
- Matthew Shane Loop
Institutions
- University of North Carolina at Chapel Hill (US)
- Itron (United States) (US)
- University of Basel (CH)
- Auburn University (US)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-01-12
- DOI
- https://doi.org/10.3389/fphar.2025.1664808
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- University of North Carolina at Chapel Hill
- National Institute of General Medical Sciences